INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46h ago
HOUSE PTR6h ago
SEC 13F6h ago
ROBINHOOD CHAIN6h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Jordan Julie sold NGNE

Chief Medical Officer · Neurogene Inc. · Common Stock

Side
SELL
Value
$18K
Shares
828
Price
$21.89
Executed
Mar 26, 2026
Disclosed
Mar 30, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Mar 26 executedMar 30, 2026 disclosed

NGNE · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+5 / 25

    $18K reported value · 6.2% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NGNE

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    SC
    Shafer ChristinaChief Commercial Officer
    NGNENeurogene Inc.
    Grant or award
    		A—
    120.0K sh
    		May 5, 2026May 7, 2026
    traded May 5, 2026
    		+2dSEC FORM 4

    Evidence

    9
    WK
    Woods KeithDirector
    NGNENeurogene Inc.
    Grant or award
    		A—
    12.1K sh
    		Feb 20, 2026Feb 24, 2026
    traded Feb 20, 2026
    		+4dSEC FORM 4

    Evidence

    21
    CS
    Cobb StuartChief Scientific Officer
    NGNENeurogene Inc.
    Grant or award
    		A—
    16.5K sh
    		Feb 20, 2026Feb 24, 2026
    traded Feb 20, 2026
    		+4dSEC FORM 4

    Evidence

    9
    JJ
    Jordan JulieChief Medical Officer
    NGNENeurogene Inc.
    Grant or award
    		A—
    29.6K sh
    		Feb 20, 2026Feb 24, 2026
    traded Feb 20, 2026
    		+4dSEC FORM 4

    Evidence

    21
    JJ
    Jordan JulieChief Medical Officer
    NGNENeurogene Inc.
    Grant or award
    		A—
    4,900 sh
    		Feb 20, 2026Feb 24, 2026
    traded Feb 20, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001968554-26-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 26, 2026
    Published
    Mar 30, 2026
    Ingested by INSIDER
    Nov 5, 04:08 UTC
    Last re-read
    Nov 5, 04:08 UTC

    Extracted facts

    Filer
    Jordan Julie
    Role
    Chief Medical Officer
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Neurogene Inc.
    Ticker
    NGNE
    Shares
    828
    Price per share
    $21.89
    Value
    $18,128
    Execution date (reported)
    Mar 26, 2026
    Owned after transaction
    12.5K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 828
    • Price: $21.8932

    = $18,128

    What this establishes

    Jordan Julie filed this Form 4 reporting a open-market sale of NGNE on Mar 26, 2026. It became public on Mar 30, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Medical Officer
    Jordan Juliecik:0001968554
    Issuer
    Neurogene Inc.cik:0001404644

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.